PL404273A1 - Azotan (III) 3-karbamoilo-1-metylopirydyniowy, sposób jego otrzymywania i zastosowanie - Google Patents
Azotan (III) 3-karbamoilo-1-metylopirydyniowy, sposób jego otrzymywania i zastosowanieInfo
- Publication number
- PL404273A1 PL404273A1 PL404273A PL40427313A PL404273A1 PL 404273 A1 PL404273 A1 PL 404273A1 PL 404273 A PL404273 A PL 404273A PL 40427313 A PL40427313 A PL 40427313A PL 404273 A1 PL404273 A1 PL 404273A1
- Authority
- PL
- Poland
- Prior art keywords
- carbamoyl
- iii
- preparation
- methylpyridinium
- endothelial
- Prior art date
Links
- LDHMAVIPBRSVRG-UHFFFAOYSA-O 1-methylnicotinamide Chemical compound C[N+]1=CC=CC(C(N)=O)=C1 LDHMAVIPBRSVRG-UHFFFAOYSA-O 0.000 title abstract 2
- 229910002651 NO3 Inorganic materials 0.000 title abstract 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000003511 endothelial effect Effects 0.000 abstract 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 abstract 1
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 229960001123 epoprostenol Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000002666 vasoprotective effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Wynalazek dotyczy nowej soli pirydyniowej zawierającej anion jako azotan(III) i kation jako 3-karbamoilo-1-metylopirydyniowy, sposobu jej otrzymywania oraz zastosowania do wytwarzania środka naczynio-protekcyjnego do leczenia lub profilaktyki stanów lub chorób związanych z dysfunkcją śródbłonka naczyniowego, niewydolnością śródbłonkowej syntezy tlenku azotu (NO) i/lub niewydolnością śródbłonkowej syntezy prostacykliny (PGI2).
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL404273A PL226999B1 (pl) | 2013-06-11 | 2013-06-11 | Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie |
| PCT/PL2014/050036 WO2014200373A1 (en) | 2013-06-11 | 2014-06-10 | 3-carbamoyl-1 -methylpyridinium nitrite, process for its preparation and its use |
| EP14741689.5A EP3008041B1 (en) | 2013-06-11 | 2014-06-10 | 3-carbamoyl-1-methylpyridinium nitrite, process for its preparation and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL404273A PL226999B1 (pl) | 2013-06-11 | 2013-06-11 | Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL404273A1 true PL404273A1 (pl) | 2014-12-22 |
| PL226999B1 PL226999B1 (pl) | 2017-10-31 |
Family
ID=51211835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL404273A PL226999B1 (pl) | 2013-06-11 | 2013-06-11 | Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3008041B1 (pl) |
| PL (1) | PL226999B1 (pl) |
| WO (1) | WO2014200373A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018015862A1 (en) * | 2016-07-18 | 2018-01-25 | Pharmena S.A. | 1-methylnicotinamide salts for use in raising the blood levels of adiponectin |
| JP2019521160A (ja) * | 2016-07-18 | 2019-07-25 | ファルメナ エスエー | Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド |
| WO2021195027A1 (en) | 2020-03-27 | 2021-09-30 | Waters Technologies Corporation | Sample automation manager |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL364348A1 (pl) * | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego |
-
2013
- 2013-06-11 PL PL404273A patent/PL226999B1/pl unknown
-
2014
- 2014-06-10 WO PCT/PL2014/050036 patent/WO2014200373A1/en active Application Filing
- 2014-06-10 EP EP14741689.5A patent/EP3008041B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014200373A1 (en) | 2014-12-18 |
| EP3008041B1 (en) | 2019-09-18 |
| PL226999B1 (pl) | 2017-10-31 |
| EP3008041A1 (en) | 2016-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015003355A1 (es) | Derivados del bipirazol como inhibidores jak | |
| JOP20170100B1 (ar) | توليف مركبات إندازول | |
| PH12017500833A1 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| EA201890373A1 (ru) | Пиридиновые соединения, пригодные для борьбы с фитопатогенными грибами | |
| MX2016008085A (es) | Procedimiento para la preparacion de cetonas fenoxifenilicas sustituidas. | |
| MX2019006609A (es) | Polvo de acero inoxidable para producir acero inoxidable sinterizado duplex. | |
| NZ719568A (en) | Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative | |
| JO3487B1 (ar) | تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به | |
| JOP20170101B1 (ar) | توليف مركبات إندازول | |
| SG11201707899SA (en) | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same | |
| UA116640C2 (uk) | Спосіб виробництва танталових сплавів | |
| PL404273A1 (pl) | Azotan (III) 3-karbamoilo-1-metylopirydyniowy, sposób jego otrzymywania i zastosowanie | |
| BR112017012993A2 (pt) | processo catalítico para produzir propileno glicol pela redução seletiva de glicerol, catalisador e processo para produzir o catalisador | |
| MY186470A (en) | Plating bath and method for electroless deposition of nickel layers | |
| MX2015014728A (es) | Sintesis de inhibidores de beta secretasa (bace). | |
| EA201591449A1 (ru) | Способы получения противораковых композиций | |
| MX2018013382A (es) | Produccion de dioxido de titanio nanoparticulado. | |
| GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
| MX2016005511A (es) | Intermediarios y metodos para sintetizar derivados de calicheamicina. | |
| MY187078A (en) | Process of production of 7,8-dihydro-c15-aldehyde | |
| MY190171A (en) | Synthesis of indazoles | |
| PL411770A1 (pl) | Związki makrocykliczne z podstawnikiem cukrowym w pozycji lariatowej, sposób wytwarzania oraz zastosowanie | |
| PL408436A1 (pl) | Sposób regeneracji roztworów poabsorpcyjnych zawierających związki kompleksowe żelaza | |
| EA201990524A1 (ru) | Способ получения замещенных оксиранов и триазолов | |
| IN2014MU00069A (pl) |